Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

EXPLAINED: 24 | Rare Historical Photos

Tragedy as girl, 18, dies of blood clot two weeks after Covid vaccine

Kasey Turner experienced 'thunder clap' headaches from thrombosis in her sinus cavity

Manchester Evening News

Testament to protecting millions of lives

The race against time to safely develop and quickly deliver a life-saving COVID-19 vaccine around the world serves as AstraZeneca's testament to protecting the lives of billions of people while addressing one of the biggest healthcare crises facing humankind.

Bangkok Post

Student paramedic, 18, died of clot two weeks after having Covid vaccine

Kasey suffered the worst headache of her life and went to hospital, where she died four days later

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

'Healthy' teen dies just days after suffering 'thunderclap headache' from Covid jab

Kasey Turner was rushed to intensive care with an acute onset headache last February.

Daily Record

'Healthy' teen died after suffering 'thunderclap headache' following AstraZeneca Covid jab

Kasey Turner, 18, died four days after being admitted to Barnsley Hospital, having received her first dose of the AstraZeneca Covid vaccine

Daily Mirror

AstraZeneca's COVID-19 Vaccine Expected To Win European Approval This Week: Reuters

European Medicines Agency is expected to approve AstraZeneca Plc's (NASDAQ: AZN) antibody-based COVID-19 vaccine for preventing COVID-19 infections,

Benzinga

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 1.6% on an annualized basis producing an average annual return of 15.33%. Currently, AstraZeneca has a market capitalization of $198.08 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents

Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint.

Benzinga

AstraZeneca COVID Drug Neutralizes Omicron Sub-Variants in Lab Study

AstraZeneca said on Monday its antibody-based cocktail to prevent and treat COVID-19 retained neutralizing activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study. This is the first data looking at the impact of AstraZeneca's Evusheld treatment on "cousins" of the Omicron variant following…

Asharq Al-Awsat

Oxford Covid jab gears up for final act: saving the rest of the world

After mishaps and misinformation, jab will build ‘global wall of immunity’, says director of Oxford Vaccine Group

The Guardian - UK

'Do the right thing' Husband who lost wife to AstraZeneca Covid vaccine demands government compensation

Nicola Weideling suffered catastrophic bleeds on her brain after being hospitalised with blood clots caused by the jab

Wales Online

AstraZeneca Mulls Ditching US Approval For Its COVID-19 Vaccine: FT

Citing AstraZeneca Plc's (NASDAQ: AZN) head of research and development, the Financial Times reported that the Company

Benzinga

The Midlands transport specialist that has helped AstraZeneca ship 300m vaccine doses around the world

'We’re extremely proud of our expertise and achievements and are honoured to contribute to this global vaccine rollout'

Birmingham Post

AstraZeneca vs. Johnson & Johnson: Which Drug Manufacturer is a Better Buy?

The COVID-19 pandemic has boosted the revenues of most drug manufacturers. And since healthcare expenditure has been climbing steadily, and because the global population is aging, the demand for medicines is expected to grow. Quality drug manufacturers AstraZeneca (AZN) and Johnson & Johnson (JNJ) should benefit from this trend. But…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

AstraZeneca’s Evusheld Covid-prevention drug gets UK approval

Treatment aimed at people who cannot be vaccinated is boost to firm’s coronavirus portfolio

Benzinga

Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron

Clover Biopharmaceuticals Ltd's follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and durable protection in individuals five months after the second dose. The follow-up analysis involved 26,400 individuals. Against any variant, efficacy was maintained at 100% against severe COVID-19 and 95% against COVID-19 associated…

The Guardian - UK

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

Benzinga

AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai

Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ: AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris (ravulizumab).

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Asharq Al-Awsat

Astrazeneca: Our Vaccine Helped Save More Than One Million Lives

In the global fight against "Covid-19”, AstraZeneca has become a household name for millions of people around the world. It has supplied over 2.7 billion doses of the vaccine globally, with approximately two-thirds going to low- and middle-income countries, according to Mene Pangalos Executive Vice-President, BioPharmaceuticals R&D. In a wide-ranging…

Benzinga

Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody

European Medicines Agency has started reviewing AstraZeneca Plc's (NASDAQ:AZN) application for antibody-based COVID-19 therapy but gave no timeline for a conclusion. Infections from COVID-19 are still rising in parts of the world, including Europe. On Tuesday, China posted a steep jump in daily COVID-19 infections, with new cases more than doubling from a…

Reuters

Europe begins reviewing application for AstraZeneca COVID drug

Europe's drug regulator said on Tuesday it had begun reviewing AstraZeneca Plc's application for antibody-based COVID-19 therapy, a key step towards approval of the treatment in the region, but gave no timeline for a conclusion.

Benzinga

FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition

The FDA has declined to approve AstraZeneca Plc's (NASDAQ:AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and stuffiness. The FDA has issued a complete response letter following AstraZeneca's application to extend the use of Fasenra and requested additional clinical data…

The Independent UK

Counting vaccine donations as foreign aid will allow UK to cut £140m from budget

New international guidelines may even allow Britain and other western countries to claim back substantially more money than they paid for vaccine supplies

AAP

Vaccine caused Tas man's death: Coroner

A Tasmanian father of four died from adverse effects of the AstraZeneca coronavirus vaccine, a coroner has found.

1 … 23 24 25 26

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.